<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
INMB
INmune Bio
$
()


  • INmune Bio to sell 986,000 shares at $9.84 in registered direct offering

    Today - 09:09am
  • INmune Bio announces 24-month stability validation of XPro

    4/23/2024 - 08:06am
  • INmune Bio raises $4.8M in gross proceeds through registered direct offering

    4/22/2024 - 08:12am
  • INmune Bio presents data on INB03's role as immune check point

    4/8/2024 - 08:19am
  • INmune Bio reports 'significant' EEG improvement in patients treated with Xpro

    3/5/2024 - 08:11am
  • INmune Bio announces FDA removal of clinical hold for Alzheimer disease program

    1/30/2024 - 08:05am
  • Biotech Alert: Searches spiking for these stocks today

    1/18/2024 - 11:32am
  • Elevai Labs signs worldwide license agreement with INmune Bio

    1/16/2024 - 08:43am
  • INmune Bio doses first patient in Phase 1/2 study of INKmune

    1/2/2024 - 08:06am
  • Fly Intel: After-Hours Movers

    12/18/2023 - 18:54pm
  • INmune Bio announces Alzheimer's trial remains on hold

    12/18/2023 - 16:08pm
  • INmune Bio announces presentation on use of INB03

    11/29/2023 - 08:05am
  • INmune receives EMA authorization in France, Spain for Phase II trial of XPro

    11/27/2023 - 08:18am
  • INmune Bio announces expansion of Phase II trial for AD in Europe

    11/15/2023 - 09:07am
  • INmune Bio updates on patent covering INB16, INKmune therapeutic composition

    10/31/2023 - 08:13am
dynamic_feed Breaking News